美國
US 12,697,314 B2
Pharmaceutical composition for treating autosomal dominant polycystic kidney disease
US 12,697,314 B2 是美國專利商標局（USPTO）的核准專利，日期 2026-08-04。申請人：NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY; KYOTO UNIVERSITY。PDF 可在本頁下載，未登入每天最多 5 篇。
- 申請人
- NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY; KYOTO UNIVERSITY
- 發明人
- Kenji OSAFUNE; Shinichi MAE; Saori NISHIO; Fumihiko HATTANDA; Tsuyoshi NAKANO; Ryuichiro HIRAYAMA; Tomoko SUZUKI; Ayuto HAYASHI
- 公開日
- 2026-08-04
- 申請日
- 2025-06-18
- 文件種類
- B2 核准公告
- 也寫作
- US 12,697,314 B2 · US12697314 · 12697314
摘要
A new dosage regimen of a pharmaceutical composition comprising tamibarotene as the active ingredient for treating autosomal dominant polycystic kidney disease. A pharmaceutical composition comprising tamibarotene for the treatment or prevention of autosomal dominant polycystic kidney disease (ADPKD), wherein the composition is administered orally to a patient with ADPKD in an amount of 1.4-5.5 mg/day, particularly 4.0 mg/day of tamibarotene.
這裡只列摘要開頭，完整內容在 PDF 裡。
不用登入，每天可下載 5 篇（今天還剩 5 篇）。批次下載與 OA 引證整理需免費註冊。
專利局網站： 美國專利商標局（USPTO）